Biotech News - Sangamo BioSciences to Present at the BioCentury Future Leaders in the Biotech

Sangamo BioSciences to Present at the BioCentury Future Leaders in
the Biotech Industry Conference

RICHMOND, Calif., March 23 /PRNewswire-FirstCall/ -- Sangamo
BioSciences, Inc. (NASDAQ:SGMO) announced today that it will be
presenting at the BioCentury and Thomson Financial Future Leaders in
the Biotech Industry Conference at 10:00 a.m. Eastern Time on
Thursday, March 30, 2006 at the Millennium Broadway Hotel in New
York. Edward Lanphier, Sangamo's president and chief executive
officer, will provide an overview of the company's business strategy
and an update on the progress of Sangamo's therapeutic development
programs.

The presentation will be webcast live and may be accessed via a link
on the Sangamo BioSciences website in the Investor Relations section
under "Company Overview" http://phx.corporate-ir.net/phoenix.zhtml?
c=0938&p==irol-IRHome . The presentation will be archived on the
Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development
of novel DNA-binding proteins for therapeutic gene regulation and
modification. The most advanced ZFP Therapeutic(TM) development
programs are currently in Phase 1 clinical trials for evaluation of
safety in patients with diabetic neuropathy and peripheral artery
disease. Other therapeutic development programs are focused on
macular degeneration, ischemic heart disease, congestive heart
failure, neuropathic pain, and infectious and monogenic diseases.
Sangamo's core competencies enable the engineering of a class of DNA-
binding proteins known as zinc finger DNA-binding proteins (ZFPs).
By engineering ZFPs that recognize a specific DNA sequence Sangamo
has created ZFP transcription factors (ZFP TFTM) that can control
gene expression and, consequently, cell function. Sangamo is also
developing sequence-specific ZFP Nucleases (ZFNTM) for therapeutic
gene modification as a treatment for a variety of monogenic
diseases, such as sickle cell anemia, and for infectious diseases,
such as HIV. Sangamo has established several Enabling Technology
Agreements with companies to apply its ZFP Technology to enhance the
production of protein pharmaceuticals. For more information about
Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on
Sangamo's current expectations. These forward-looking statements
include, without limitation, references to the research and
development of novel ZFP TFs and ZFNs, applications of Sangamo's ZFP
TF technology platform and clinical trials of ZFP Therapeutics.
Actual results may differ materially from these forward-looking
statements due to a number of factors, including technological
challenges, uncertainties relating to the initiation and completion
of stages of the ZFP Therapeutic clinical trials, Sangamo's ability
to develop commercially viable products and technological
developments by our competitors. See the company's SEC filings, and
in particular, the risk factors described in the company's Annual
Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences,
Inc. assumes no obligation to update the forward-looking information
contained in this press release.

Source: Sangamo BioSciences, Inc.

CONTACT: Elizabeth Wolffe, Ph.D., Sangamo BioSciences, Inc.,
+1-510-970-6000, ext. 271, ewolffe@sangamo.com; or Media, Justin
Jackson,
+1-212-213-0006, jjackson@burnsmc.com, for Sangamo BioSciences, Inc.

Web site: http://www.sangamo.com/

http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/